MCID: SRS001
MIFTS: 51

Serous Cystadenocarcinoma malady

Cancer diseases category

Summaries for Serous Cystadenocarcinoma

About this section


Disease Ontology:9 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary: Serous Cystadenocarcinoma, also known as serous cystadenocarcinoma, nos, is related to cystadenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are Ovarian Infertility Genes and Plasma membrane estrogen receptor signaling. The compounds tanshinone iia and toremifene have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and colon, and related mouse phenotypes are pigmentation and hearing/vestibular/ear.

Wikipedia:63 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. more...

Aliases & Classifications for Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 11DISEASES, 43Novoseek, 60UMLS, 33MeSH, 55SNOMED-CT, 38NCIt
See all sources

Serous Cystadenocarcinoma, Aliases & Descriptions:

Name: Serous Cystadenocarcinoma 9 11
Serous Cystadenocarcinoma, Nos 9
Cystadenocarcinoma, Serous 60
 
Cystadenocarcinoma Serous 43
Serous Adenocarcinoma 9
Serous Carcinoma 9


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


External Ids:

Disease Ontology9 DOID:3114
MeSH33 D018284
SNOMED-CT55 90725004, 189685001

Related Diseases for Serous Cystadenocarcinoma

About this section

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 158)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma32.6MUC16
2ovarian serous cystadenocarcinoma31.6UBE4A, ZNF217, MUC16, USP2, USP14
3adenofibroma31.1MUC16
4bilateral breast cancer30.6ESR1, PGR
5breast cancer30.5ESR1, PGR
6leiomyosarcoma30.5MUC16, PGR, TP53
7lymphangioleiomyomatosis30.4PGR, ESR1
8angiomyolipoma30.3PGR, ESR1
9leiomyoma30.2CYP19A1, PGR, ESR2, ESR1
10endometrial cancer30.1TP53, PGR, ESR2, ESR1, MUC16, BCL2
11malignant mixed mullerian tumor30.0TP53, PGR
12endometriosis30.0CYP19A1, VEGFA, PGR, ESR2, ESR1, MUC16
13transitional cell carcinoma29.9TP53, MUC16, BIRC5, CDKN1A
14astrocytoma29.7VEGFA, TP53, AKT1, CDKN1A
15adenocarcinoma29.5ESR1, ESR2, PGR, TP53, VEGFA, MUC16
16leukemia29.2TP53, ESR2, FAS, AKT1, BCL2, BIRC5
17melanoma28.9VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
18pancreatic serous cystadenocarcinoma10.6
19cerebral meningioma10.5PGR
20pericardial effusion10.5MUC16
21peritonitis10.5
22peritoneal mesothelioma10.4
23peritoneal serous adenocarcinoma10.4
24ovarian disease10.4CYP19A1, MUC16
25pancreatitis10.4
26estrogen excess10.4CYP19A1, PGR
27endophthalmitis10.4VEGFA
28fallopian tube serous adenocarcinoma10.4
29cervical serous adenocarcinoma10.4
30uterine corpus serous adenocarcinoma10.4
31uterine ligament serous adenocarcinoma10.4
32ovary serous adenocarcinoma10.4
33progesterone resistance10.3ESR1, PGR
34ovarian cyst10.3CYP19A1, ESR2, MUC16
35endocrine gland cancer10.3ESR1, CYP19A1
36breast fibroadenoma10.3ESR1, PGR
37uterine sarcoma10.3CYP19A1, ESR1
38sertoli cell tumor10.3CYP19A1, PGR
39cribriform carcinoma10.3ESR1, PGR
40meningioma, familial10.3ESR1, PGR
41mammary paget's disease10.3PGR, ESR1
42hepatitis10.3
43teratoma10.3
44cutaneous t cell lymphoma10.3FAS, BIRC5, BAX
45leiomyomatosis10.3PGR, ESR1
46adenosarcoma10.3PGR, ESR1
47breast disease10.3PGR, ESR1
48abrikosov's tumor10.3MUC16, ESR1, CYP19A1
49ovarian hyperstimulation syndrome10.3CYP19A1, VEGFA
50uterine fibroid10.2ESR1, PGR

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to serous cystadenocarcinoma

Symptoms for Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Serous Cystadenocarcinoma

Search NIH Clinical Center for Serous Cystadenocarcinoma

Genetic Tests for Serous Cystadenocarcinoma

About this section

Anatomical Context for Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

31
Ovary, Pancreas, Colon, Breast, Bone, Lymph node, Spleen, Liver, Testis

Animal Models for Serous Cystadenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

35 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.4BCL2, FAS, TP53, CYP19A1
2MP:00053779.2CYP19A1, ESR2, FAS, BCL2, BAX, CDKN1A
3MP:00053758.9CYP19A1, TP53, ESR2, ESR1, AKT1, BCL2
4MP:00053718.6VEGFA, TP53, PGR, ESR2, ESR1, FAS
5MP:00053708.6CYP19A1, VEGFA, TP53, ESR2, ESR1, FAS
6MP:00053918.5VEGFA, TP53, FAS, BCL2, BAX, CDKN1A
7MP:00028738.5PPP2R1A, CYP19A1, VEGFA, TP53, PGR, ESR2
8MP:00053818.5VEGFA, TP53, ESR2, ESR1, FAS, BCL2
9MP:00053888.4VEGFA, TP53, ESR2, ESR1, FAS, AKT1
10MP:00020068.2PPP2R1A, VEGFA, TP53, PGR, ESR2, ESR1
11MP:00053678.1USP2, VEGFA, TP53, ESR2, ESR1, FAS
12MP:00053808.1VEGFA, TP53, PGR, NANOG, ESR1, AKT1
13MP:00053977.8CYP19A1, VEGFA, TP53, PGR, ESR2, ESR1
14MP:00030127.8USP2, VEGFA, TP53, PGR, NANOG, ESR2
15MP:00053877.8ESR2, PGR, TP53, VEGFA, CYP19A1, ESR1
16MP:00053857.7CYP19A1, USP2, VEGFA, TP53, PGR, ESR2
17MP:00053797.6CYP19A1, USP2, VEGFA, TP53, PGR, ESR2
18MP:00053907.5TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
19MP:00053697.5TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
20MP:00107717.4TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
21MP:00036317.3CYP19A1, USP14, VEGFA, TP53, ESR2, ESR1
22MP:00053787.1TP53, VEGFA, USP14, CYP19A1, PPP2R1A, ESR2
23MP:00053896.7CDKN1A, CYP19A1, USP14, USP2, VEGFA, TP53
24MP:00053866.4TP53, VEGFA, USP2, USP14, CYP19A1, PPP2R1A
25MP:00053846.4NANOG, PGR, TP53, VEGFA, USP14, CYP19A1
26MP:00107686.3NANOG, PGR, TP53, VEGFA, USP14, PPP2R1A
27MP:00053766.2TP53, VEGFA, USP2, USP14, CYP19A1, PPP2R1A

Publications for Serous Cystadenocarcinoma

About this section

Articles related to Serous Cystadenocarcinoma:

(show top 50)    (show all 90)
idTitleAuthorsYear
1
Paratesticular papillary serous cystadenocarcinoma: A rare entity in Indian population. (25308020)
2014
2
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. (25017255)
2014
3
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. (24595078)
2013
4
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. (23370947)
2013
5
Serous cystadenocarcinoma of pancreas. (23763806)
2013
6
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
7
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. (23040941)
2012
8
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. (22400805)
2012
9
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. (22066125)
2011
10
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. (20163045)
2009
11
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. (18818939)
2009
12
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. (19459016)
2009
13
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. (19564753)
2009
14
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. (19060596)
2008
15
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
16
Paratesticular papillary serous cystadenocarcinoma--a case report. (16625973)
2006
17
Serous cystadenocarcinoma of the pancreas: management of a rare entity. (16025006)
2005
18
Primary papillary serous cystadenocarcinoma of broad ligament. (15845057)
2005
19
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. (15032078)
2004
20
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. (14551796)
2004
21
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. (15025299)
2003
22
Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. (12068151)
2002
23
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
24
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
25
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
26
Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary. (9642449)
1998
27
Serous cystadenocarcinoma and ovarian teratoma during pregnancy. (8737305)
1996
28
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. (8774651)
1996
29
Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary. (7737584)
1995
30
Stage III papillary serous cystadenocarcinoma of the ovary in a 15-year-old female. (8188094)
1994
31
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. (9205465)
1994
32
Heterophile antigens in serous cystadenocarcinoma of the human ovary. (1283511)
1992
33
A rare case of serous cystadenocarcinoma of the pancreas. (1568167)
1992
34
Successful pregnancy after conservative surgery for ovarian papillary serous cystadenocarcinoma of low malignant potential. (1785199)
1991
35
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
36
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (2482644)
1989
37
Primary tumor of the rectovaginal septum: mesothelioma or papillary serous cystadenocarcinoma. A case report with transmission electron microscopy. (3668422)
1987
38
An amylase-producing serous cystadenocarcinoma of the ovary. (2409494)
1985
39
Serous cystadenocarcinoma as incidental finding during a repeat cesarean section. (4037003)
1985
40
Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. (6744227)
1984
41
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (6206939)
1984
42
Occurrence of bone in serous cystadenocarcinoma of the ovary. (6816209)
1982
43
Mixed Mullerian tumour of ovary in association with breast carcinoma and serous cystadenocarcinoma carcinoma of other ovary. (6273302)
1981
44
Nature of carcinoembryonic antigen purified from malignant ascitic fluid of serous cystadenocarcinoma of the ovary. (7300840)
1981
45
Classification and survival rate of patients with serous cystadenocarcinoma of the ovaries. (1004656)
1976
46
An immunologic comparison between serous cystadenocarcinoma of the ovary and other human gynecologic tumors. (4126800)
1973
47
Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor-associated antigens. (4632680)
1973
48
Hypoglycemia associated with serous cystadenocarcinoma of the ovary. (4189963)
1970
49
Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. (4910128)
1970
50
Disseminated endosalpingiosis associated with bilateral papillary serous cystadenocarcinoma of the ovaries. A case report. (13909448)
1962

Variations for Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for genes affiliated with Serous Cystadenocarcinoma

About this section

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 90)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.8ESR2, PGR, CYP19A1
29.8AKT1, ESR1, ESR2
3
Show member pathways
9.8TP53, CDKN1A
49.8AKT1, BCL2, BAX
5
Show member pathways
9.8ESR2, ESR1, CYP19A1
6
Show member pathways
9.8BAX, FAS, BCL2
79.8AKT1, ESR1, BCL2
89.7BIRC5, AKT1, TP53
99.6BIRC5, AKT1, BCL2, BAX
10
Show member pathways
FAS pathway and Stress induction of HSP regulation36
Apoptosis and survival FAS signaling cascades58
Caspase cascade in apoptosis36
9.6BAX, FAS, BCL2, AKT1
119.5BAX, BCL2, ESR1, ESR2
12
Show member pathways
IL23-mediated signaling events36
Immune response IL 10 signaling pathway58
Angiopoietin receptor Tie2-mediated signaling36
Development PDGF signaling via STATs and NF kB58
Development Angiopoietin Tie2 signaling58
9.5BIRC5, BCL2, CDKN1A, AKT1
13
Show member pathways
9.5PPP2R1A, AKT1, BCL2, BAX
14
Show member pathways
9.5BCL2, BAX, AKT1, TP53
15
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
9.5BCL2, BAX, AKT1, TP53
16
Show member pathways
9.5BCL2, AKT1, BAX, TP53
17
Show member pathways
Cell cycle ESR1 regulation of G1 S transition58
Immune response MIF JAB1 signaling58
Cell cycle Cell cycle generic schema 58
9.4CDKN1A, PGR, AKT1, ESR1
189.4CDKN1A, BCL2, AKT1, VEGFA
199.4AKT1, TP53, BAX, CDKN1A
20
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway58
Signal transduction AKT signaling58
9.4TP53, BAX, CDKN1A, AKT1
21
Show member pathways
DNA damage response36
9.4CDKN1A, BAX, FAS, TP53
22
Show member pathways
Prolactin Signaling Pathway36
Development Prolactin receptor signaling58
Leptin signaling pathway36
9.3ESR2, ESR1, BCL2, BAX, AKT1
23
Show member pathways
9.3BAX, BCL2, TP53, CDKN1A
24
Show member pathways
9.3CDKN1A, VEGFA, TP53, AKT1
259.3AKT1, CDKN1A, TP53, PPP2R1A
269.3CDKN1A, VEGFA, TP53, BCL2
27
Show member pathways
9.2BCL2, TP53, AKT1, BAX, FAS
28
Show member pathways
Apoptosis and survival TNFR1 signaling pathway58
TWEAK Signaling Pathway36
Apoptosis Modulation by HSP7036
HIV-1 Nef- Negative effector of Fas and TNF-alpha36
9.2BAX, FAS, AKT1, BCL2, TP53
299.2TP53, CDKN1A, BAX, AKT1, BIRC5
309.1CDKN1A, BCL2, FAS, BAX, TP53
31
Show member pathways
Signaling Pathways in Glioblastoma36
9.1CDKN1A, TP53, AKT1, BCL2, VEGFA
32
Show member pathways
9.0AKT1, TP53, FAS, BCL2, BIRC5, BAX
33
Show member pathways
Apoptosis Modulation and Signaling36
Apoptosis36
9.0BCL2, BAX, BIRC5, AKT1, FAS, TP53
34
Show member pathways
Development EGFR signaling via PIP358
Development PDGF signaling via MAPK cascades58
Apoptosis and survival Anti apoptotic action of membrane bound ESR158
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases58
Development Neurotrophin family signaling58
Apoptosis and survival NGF signaling pathway58
Apoptosis and survival Role of CDK5 in neuronal death and survival58
9.0BAX, BCL2, TP53, AKT1, FAS, ESR1
35
Show member pathways
Signal transduction PTEN pathway58
9.0CDKN1A, TP53, AKT1, BCL2, BIRC5, BAX
36
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways58
8.9BIRC5, BCL2, FAS, TP53, BAX, CDKN1A
37
Show member pathways
8.9BAX, CDKN1A, BCL2, AKT1, FAS, TP53
38
Show member pathways
8.8TP53, AKT1, BAX, BCL2, CDKN1A, PPP2R1A
398.8TP53, CDKN1A, PPP2R1A, VEGFA, AKT1, BCL2
408.7VEGFA, BAX, BCL2, CYP19A1, ESR1, TP53
41
Show member pathways
Proteasome Degradation36
Immune response Antigen presentation by MHC class I58
8.6AKT1, TP53, BAX, BCL2, PPP2R1A, FAS
428.4VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
43
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
8.4CDKN1A, BAX, AKT1, TP53, PPP2R1A, BIRC5
44
Show member pathways
8.4AKT1, ESR1, ESR2, PPP2R1A, CDKN1A, TP53
45
Show member pathways
8.4ESR1, ESR2, PPP2R1A, CDKN1A, BCL2, AKT1
46
Show member pathways
8.3VEGFA, PPP2R1A, CDKN1A, BAX, BCL2, AKT1
47
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
8.2NANOG, TP53, PPP2R1A, AKT1, CDKN1A, BCL2
488.2ESR1, CDKN1A, AKT1, FAS, VEGFA, NANOG
498.2BCL2, BAX, CDKN1A, ESR1, ESR2, TP53

Compounds for genes affiliated with Serous Cystadenocarcinoma

About this section

Compounds related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 245)
idCompoundScoreTop Affiliating Genes
1tanshinone iia439.7BCL2, BAX, TP53, FAS
2toremifene43 1210.6FAS, ESR1, ESR2, PGR, CYP19A1
3hoechst 33342439.5BAX, CDKN1A, BCL2, FAS, BIRC5
4trastuzumab43 49 1211.3CYP19A1, VEGFA, FAS, ESR1, BIRC5, PGR
5noxa439.3BAX, CDKN1A, FAS, TP53, BCL2, BIRC5
6suberoylanilide hydroxamic acid439.3TP53, CDKN1A, BAX, BIRC5, BCL2, FAS
73,3-diindolylmethane439.3BAX, BIRC5, ESR1, TP53, VEGFA, CDKN1A
8mifepristone43 28 59 1212.2VEGFA, CYP19A1, ESR1, ESR2, BIRC5, BAX
9cd 437439.2CDKN1A, BCL2, FAS, TP53, BAX
10n-(4-hydroxyphenyl)retinamide439.2ESR1, BCL2, BAX, CDKN1A, CYP19A1, TP53
11celecoxib43 59 28 49 24 1214.2CYP19A1, AKT1, BCL2, BIRC5, VEGFA, BAX
12flavopiridol43 1210.2VEGFA, BIRC5, BAX, CDKN1A, TP53, BCL2
13gefitinib43 49 1211.2ESR1, ESR2, VEGFA, CDKN1A, BIRC5, AKT1
142-chlorodeoxyadenosine439.1FAS, TP53, BCL2, BIRC5, BAX
15bortezomib43 49 1211.1VEGFA, TP53, BCL2, BAX, CDKN1A, BIRC5
16adpribose439.0BCL2, FAS, TP53, BAX, BIRC5, CDKN1A
17sp 60012543 599.9BCL2, AKT1, BAX, CDKN1A, TP53, FAS
18indole-3-carbinol438.9CDKN1A, BAX, BIRC5, BCL2, AKT1, ESR1
19curcumin438.9TP53, BAX, AKT1, BCL2, BIRC5, CDKN1A
20adriamycin438.9PGR, FAS, AKT1, BIRC5, TP53, BCL2
21etoposide43 49 59 1211.9ESR2, FAS, BCL2, BIRC5, BAX, TP53
22gemcitabine43 49 1210.9BAX, BCL2, CDKN1A, CYP19A1, BIRC5, TP53
23thymidylate438.9BAX, FAS, CDKN1A, VEGFA, BCL2, TP53
24egcg438.8VEGFA, TP53, ESR2, FAS, BCL2, BIRC5
25geldanamycin43 49 59 1211.8VEGFA, TP53, PGR, ESR1, BIRC5, CDKN1A
26butyrate438.8CDKN1A, BAX, BCL2, AKT1, FAS, CYP19A1
27taxane438.8CDKN1A, BIRC5, ESR1, PGR, CYP19A1, TP53
28n acetylcysteine438.8TP53, BAX, FAS, AKT1, VEGFA, BCL2
29sb 20358043 599.8VEGFA, AKT1, CDKN1A, BIRC5, TP53, FAS
30cyclophosphamide43 49 1210.7BCL2, MUC16, CYP19A1, VEGFA, TP53, PGR
31arsenite43 249.7BAX, BIRC5, BCL2, AKT1, FAS, PGR
32mg 13243 599.6CDKN1A, BAX, BIRC5, BCL2, AKT1, FAS
33docetaxel43 49 59 1211.6CYP19A1, BIRC5, BCL2, ESR1, PGR, TP53
34ly294002438.5BAX, CDKN1A, BCL2, BIRC5, FAS, VEGFA
35actinomycin d438.4TP53, ESR2, FAS, AKT1, BCL2, BIRC5
36resveratrol43 59 24 1211.4BIRC5, ESR1, ESR2, PGR, TP53, VEGFA
375fluorouracil438.3BIRC5, BAX, CDKN1A, BCL2, FAS, CYP19A1
38retinoid438.3ESR1, BCL2, ESR2, CDKN1A, PGR, TP53
39genistein43 28 59 2 24 1213.3CDKN1A, BAX, BIRC5, BCL2, AKT1, FAS
40h2o2438.3ESR2, BAX, MUC16, TP53, FAS, AKT1
41progesterone43 28 59 24 1212.2ESR2, TP53, CYP19A1, PGR, ESR1, MUC16
42cisplatin43 49 59 1211.2BCL2, BIRC5, BAX, CDKN1A, FAS, MUC16
43retinoic acid43 249.2FAS, ESR1, ESR2, PGR, TP53, CYP19A1
44tamoxifen43 49 28 1211.0BCL2, BIRC5, BAX, CDKN1A, AKT1, CYP19A1
45cycloheximide438.0TP53, PGR, ESR2, ESR1, FAS, AKT1
46paraffin437.8VEGFA, CDKN1A, BAX, BCL2, AKT1, MUC16
47paclitaxel43 49 129.7CYP19A1, VEGFA, TP53, PGR, ESR1, MUC16
48estrogen437.7ESR2, ESR1, PGR, AKT1, BCL2, BIRC5
49doxorubicin43 49 129.5ESR2, BAX, CDKN1A, BIRC5, BCL2, PGR
50vegf437.2FAS, MUC16, ESR1, ESR2, PGR, TP53

GO Terms for genes affiliated with Serous Cystadenocarcinoma

About this section

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:004693010.0BCL2, BAX
2mitochondrial outer membraneGO:00057419.8BAX, BCL2, PGR
3membraneGO:00160208.9PPP2R1A, CYP19A1, VEGFA, ESR1, BCL2
4cytosolGO:00058298.3PPP2R1A, TP53, FAS, AKT1, BCL2, BIRC5
5nucleoplasmGO:00056547.5CDKN1A, RSF1, TP53, PGR, NANOG, ESR2
6nucleusGO:00056346.4NANOG, TP53, USP2, RSF1, PPP2R1A, ESR2

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:000692410.4AKT1, FAS
2regulation of nitrogen utilizationGO:000680810.4BAX, BCL2
3transformed cell apoptotic processGO:000692710.4FAS, BAX
4regulation of protein heterodimerization activityGO:004349710.4BCL2, BAX
5regulation of protein homodimerization activityGO:004349610.4BCL2, BAX
6endoplasmic reticulum calcium ion homeostasisGO:003246910.4BAX, BCL2
7uterus developmentGO:006006510.4ESR2, ESR1
8renal system processGO:000301410.4FAS, BCL2
9response to acidGO:000110110.3BCL2, BAX
10B cell lineage commitmentGO:000232610.3BCL2, TP53
11vagina developmentGO:006006810.2ESR2, ESR1, BAX
12positive regulation of protein oligomerizationGO:003246110.2TP53, BAX
13positive regulation of nitric-oxide synthase activityGO:005100010.2AKT1, ESR1
14negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004315410.2VEGFA, AKT1, BIRC5
15extrinsic apoptotic signaling pathway via death domain receptorsGO:000862510.2BAX, BCL2, FAS
16extrinsic apoptotic signaling pathway in absence of ligandGO:009719210.2FAS, BCL2, BAX
17positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:0200124110.2PPP2R1A, FAS, BAX
18negative regulation of apoptotic signaling pathwayGO:0200123410.2BCL2, BAX
19response to salt stressGO:000965110.2BAX, TP53
20regulation of mitochondrial membrane permeabilityGO:004690210.1BCL2, TP53
21mitotic cell cycle arrestGO:007185010.1TP53, CDKN1A
22positive regulation of peptidyl-serine phosphorylationGO:003313810.1BCL2, AKT1, VEGFA
23mammary gland alveolus developmentGO:006074910.1ESR1, VEGFA
24positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.1ESR2, ESR1, AKT1
25positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:0190074010.1TP53, AKT1, BCL2
26release of cytochrome c from mitochondriaGO:000183610.1BAX, BCL2, TP53
27response to gamma radiationGO:001033210.1BAX, BCL2, TP53
28negative regulation of autophagyGO:001050710.1AKT1, BCL2
29positive regulation of intrinsic apoptotic signaling pathwayGO:0200124410.1TP53, BCL2, BAX
30neuron apoptotic processGO:005140210.1BAX, BCL2, TP53
31cellular response to organic substanceGO:007131010.0BAX, BCL2
32negative regulation of gene expressionGO:001062910.0PGR, ESR1, CDKN1A
33cellular response to glucose starvationGO:004214910.0TP53, BCL2
34androgen metabolic processGO:000820910.0CYP19A1, ESR1
35ovarian follicle developmentGO:000154110.0VEGFA, ESR2, BCL2, BAX
36response to toxic substanceGO:00096369.9CDKN1A, BAX, BCL2, FAS
37cellular response to hypoxiaGO:00714569.8VEGFA, TP53, AKT1, BCL2
38positive regulation of apoptotic processGO:00430659.8BAX, AKT1, FAS, TP53
39response to ischemiaGO:00029319.8TP53, BCL2
40protein complex assemblyGO:00064619.8PPP2R1A, TP53, FAS
41positive regulation of blood vessel endothelial cell migrationGO:00435369.7AKT1, VEGFA
42intrinsic apoptotic signaling pathwayGO:00971939.6CDKN1A, BAX, BCL2, AKT1, TP53
43positive regulation of mitotic cell cycleGO:00459319.6BIRC5, NANOG, USP2
44gene expressionGO:00104679.6PPP2R1A, PGR, ESR2, ESR1, AKT1
45negative regulation of cell growthGO:00303089.5PPP2R1A, TP53, ESR2, BCL2, CDKN1A
46apoptotic processGO:00069159.2PPP2R1A, TP53, FAS, AKT1, BCL2, BIRC5
47negative regulation of apoptotic processGO:00430669.1VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
48positive regulation of transcription from RNA polymerase II promoterGO:00459449.0VEGFA, TP53, NANOG, ESR1, AKT1
49negative regulation of transcription from RNA polymerase II promoterGO:00001228.9USP2, VEGFA, TP53, NANOG, ESR2
50regulation of transcription, DNA-templatedGO:00063558.7PPP2R1A, TP53, NANOG, ESR2, ESR1, ZNF217

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:003405610.2ESR1, ESR2
2BH3 domain bindingGO:005143410.2BAX, BCL2
3estrogen receptor activityGO:003028410.2ESR1, ESR2
4nitric-oxide synthase regulator activityGO:003023510.1ESR1, AKT1
5channel activityGO:001526710.1BAX, BCL2
6steroid bindingGO:000549610.0ESR1, ESR2, PGR
7steroid hormone receptor activityGO:000370710.0PGR, ESR2, ESR1
8core promoter sequence-specific DNA bindingGO:00010469.9ESR1, ESR2
9cyclin bindingGO:00303329.6CDKN1A, USP2
10protein phosphatase 2A bindingGO:00517219.6BCL2, TP53
11enzyme bindingGO:00198999.3TP53, PGR, ESR2, ESR1, AKT1, BIRC5
12protein heterodimerization activityGO:00469829.2PPP2R1A, VEGFA, TP53, BCL2, BIRC5, BAX
13zinc ion bindingGO:00082708.7RSF1, TP53, PGR, ESR2, ESR1, BIRC5
14identical protein bindingGO:00428028.3USP2, VEGFA, TP53, ESR1, FAS, AKT1
15protein bindingGO:00055154.6CDKN1A, PPP2R1A, RSF1, USP14, USP2, VEGFA

Products for genes affiliated with Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Serous Cystadenocarcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet